FORT LAUDERDALE, Fla., Aug. 31, 2017 -- OmniComm Systems, Inc. (OmniComm) (OTCQX:OMCM), a global leading provider of clinical data management technology, today announced that it has received certification approval from the U.S. Department of Commerce for the EU-U.S. Privacy Shield Framework program and the Swiss-U.S. Privacy Shield Framework, the successors to the U.S.-EU and U.S.-Swiss Safe Harbor Frameworks.
“This is an important achievement,” said Djuro Blanuscha, OmniComm Europe GmbH’s data protection officer. “We have made great efforts to implement the high European data protection standards throughout the entire company, and we will continue to work to ensure compliance with the related regulations in the future.”
The U.S. Department of Commerce and the European Commission developed the EU-U.S. Privacy Shield and the Swiss-U.S. Privacy Shield Frameworks “to provide companies on both sides of the Atlantic with a mechanism to comply with data protection requirements when transferring personal data from the European Union and Switzerland to the United States in support of transatlantic commerce,” according to a statement from the Privacy Shield program.
The Privacy Shield has replaced the U.S.-EU Safe Harbor Program, which was invalidated in October of 2015. More information about the Privacy Shield can be found at: https://www.privacyshield.gov
“OmniComm values and respects the confidentiality and the protection of personal data. With our commitment to comply with Privacy Shield requirements, we assure our European clients and partners that their personal information is handled in adherence to the strict European data privacy principles when it is transferred to the U.S.,” said Yvonne Rollinger, Ph.D., managing director of OmniComm Europe GmbH.
About OmniComm Systems, Inc.
OmniComm Systems, Inc. is a leading strategic software solutions provider to the life sciences industry. OmniComm is dedicated to helping the world’s pharmaceutical, biotechnology, contract research organizations, diagnostic and device firms, and academic medical centers maximize the value of their clinical research investments. Through the use of innovative and progressive technologies, these organizations drive efficiency in clinical development, better manage their risks, ensure regulatory compliance and manage their clinical operations performance. With an extensive global experience from more than 5,000 clinical trials, OmniComm provides comprehensive solutions for clinical research. For more information, visit: www.omnicomm.com
Trademarks
OmniComm, TrialMaster, TrialOne, and Promasys are registered trademarks of OmniComm Systems, Inc. Other names may be trademarks of their respective owners.
Contact Info Kuno van der Post OmniComm Systems, Inc. +1.954.473.1254 [email protected]


CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Instagram Outage Disrupts Thousands of U.S. Users
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 



